drugset / Trial / NCT07066657
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
NaSequentialOpen-labelTreatment
Summary
This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic solid tumors.
Timeline
- Start
- 2025-07-25
- Primary completion
- 2029-05
- Completion
- 2030-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MRG007 | Unknown | — | — |